Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Oncogene. 2020 Mar 2;39(17):3555–3570. doi: 10.1038/s41388-020-1235-2

Figure 3. MCT1 inhibition causes increased TCA activity in Kelly neuroblastoma cells.

Figure 3.

(A) GC-MS metabolic profiling of intracellular polar metabolite quantities in Kelly treated with 0.1μM SR13800 and vehicle treated controls for lactate, TCA intermediates α-ketoglutarate, malate and citrate, and aspartate. YSI measurements on media samples from SR13800-treated Kelly demonstrated decreased lactate secretion (B, 6h) and decreased glucose uptake (C, 24h). (D) Fractional labelling derived from 13C-glucose in TCA metabolites, succinate, fumarate, malate, α-ketoglutarate and citrate fragments in Kelly treated with 0.1μM SR13800. OCR (E) and ECAR (F) 2h post treatment with 1μM SR13800 compared to vehicle treated Kelly (n=3). (G) Relative intracellular ATP levels were determined in Kelly treated with SR13800 (n=3). *P < 0.05, **P<0.01 compared to vehicle control.